First-in-class targets in validated pathways for the right patients
Northern Biologics is a clinical stage company with a portfolio of first-in-class biologics for solid tumors.
Our approach to oncology drug development combines deep understanding of target biology and antibody mechanism of action with rigorous patient selection. This allows us to precisely target likely responders and – enabled by extensive patient biomarker data analysis in the clinic – develop rational therapies based on the specific mechanisms of our drug candidates to modulate the tumor microenvironment.
MSC-1 is a clinical stage first-in-class antibody that targets leukemia inhibitory factor (LIF), a pleiotropic cytokine that is overexpressed in most solid tumor types. LIF drives a broad program of immunosuppression in the tumor microenvironment and supports self-renewal in tumor-initiating cells (Penuelas, S. et al 2009 Cancer Cell, Shi Y. et al 2019 Nature, Wang MT. et al 2019 Nature Communications, Pascual Garcia, M. et al 2019 Nature Communications).
MSC-1 has completed an open-label, Phase Ia trial conducted in multiple study sites in Europe and North America testing MSC-1 as monotherapy in patients with relapsed or refractory metastatic solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of MSC-1, determine the recommended dose for MSC-1 monotherapy and assess the product’s preliminary activity as measured by objective response rate. Secondary objectives include assessing progression-free survival and studying MSC-1’s pharmacokinetics. MSC-1 is now Ph1b/2 ready.
Anti-periostin ‘A’ is a novel first-in-class antibody that targets periostin, a secreted matricellular protein overexpressed in the cancer stroma of most solid tumor types. Periostin has emerged as a promising target to overcome stromal mechanisms of immune escape and suppression. Anti-periostin ‘A’ is currently in IND-enabling studies.
Anti-PVR is a first-in-class antibody that inhibits PVR/CD155, a novel immune checkpoint to limit anti-tumor immunity in the tumor microenvironment. PVR/CD155 is the primary ligand for TIGIT, CD96 (inhibitory receptors) and CD226/DNAM-1 (activating receptor) expressed on T and NK cells. Inhibiting the CD155/PVR pathway provides a unique and differentiated mode of action from TIGIT antagonists. Northern Biologics has entered into an exclusive licensing partnership with Nectin Therapeutics Ltd. to develop and commercialize biologics targeting CD155 (PVR).
FLT3 agonist is a unique and highly selective agonistic antibody that activates FLT3 receptor signaling to expand dendritic cells. FLT3 agonism is an attractive approach to boost anti-tumor immune response and offers broad opportunities for combination with novel & existing immuno-oncology and cytotoxic therapies. FLT3 agonist is ready to enter IND-enabling studies.
Anti-periostin ‘B’ is a novel first-in-class antibody that targets periostin, a secreted matricellular protein overexpressed in many fibrotic diseases. Periostin is hypothesized to drive multiple fibrotic mechanisms including extracellular matrix remodelling, myofibroblast function and inflammation. Anti-periostin ‘B’ is currently at discovery stage.